Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…
NEW YORK (Reuters Health) – In terms of overall survival, carboplatin plus the oral fluoropyrimidine derivative S-1 is as effective as carboplatin plus paclitaxel in chemotherapy-naive patients with…
NEW YORK (Reuters Health) – Patients with papillary thyroid cancer who undergo lobectomy do as well as those who undergo total thyroidectomy, while external beam radiation is associated…
NEW YORK (Reuters Health) – The risk of second primary neoplasms (SPNs) of the central nervous system in survivors of childhood cancer increases greatly with the dose of…
NEW YORK (Reuters Health) – The off-label use of recombinant factor VIIa for hemostasis in patients without hemophilia confers only modest benefits but may increase the risk of…
NEW YORK (Reuters Health) – Compared with zoledronic acid, the monoclonal antibody denosumab is more effective in delaying skeletal-related events in women with breast cancer that has metastasized…
NEW YORK (Reuters Health) – The tyrosine kinase inhibitors gefitinib or erlotinib may slow the development of central nervous system metastases in patients with advanced non-small cell lung…
NEW YORK (Reuters Health) – Women with breast cancer treated with anthracycline-taxane based regimens are more likely to become amenorrheic than women treated with just anthracyclines or conventional…
NEW YORK (Reuters Health) – After first-line treatment with bevacizumab plus interferon-alpha2a, subsequent therapy with tyrosine kinase inhibitors (TKIs) improves survival in patients with metastatic renal cell carcinoma,…
NEW YORK (Reuters Health) – High-dose chemo followed by autologous stem-cell transplantation achieves good results in patients with relapsed Hodgkin’s lymphoma, and outcomes are not improved by additional…
NEW YORK (Reuters Health) – In order to minimize the risk of potential harms, erythropoiesis-stimulating agents (ESAs) in patients undergoing myelosuppressive chemotherapy should be administered at the lowest…
